Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_4
1
50%
Ph early_phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(2)

Detailed Status

Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (50.0%)
Phase 41 (50.0%)

Trials by Status

withdrawn150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
withdrawnearly_phase_1

Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress

NCT05344625
terminatedphase_4

Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients

NCT03043430

Clinical Trials (2)

Showing 2 of 2 trials
NCT05344625Early Phase 1

Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress

Withdrawn
NCT03043430Phase 4

Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2